WO2002059377A3 - Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein - Google Patents

Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein Download PDF

Info

Publication number
WO2002059377A3
WO2002059377A3 PCT/US2002/002242 US0202242W WO02059377A3 WO 2002059377 A3 WO2002059377 A3 WO 2002059377A3 US 0202242 W US0202242 W US 0202242W WO 02059377 A3 WO02059377 A3 WO 02059377A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
methods
diagnosis
compositions
modulators
Prior art date
Application number
PCT/US2002/002242
Other languages
English (en)
Other versions
WO2002059377A2 (fr
Inventor
David H Mack
Kurt C Gish
Daniel Afar
Original Assignee
Protein Design Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/829,472 external-priority patent/US20040146862A1/en
Application filed by Protein Design Labs filed Critical Protein Design Labs
Priority to CA002440703A priority Critical patent/CA2440703A1/fr
Priority to MXPA03006617A priority patent/MXPA03006617A/es
Priority to EP02713469A priority patent/EP1425302A2/fr
Priority to JP2002559859A priority patent/JP2005503760A/ja
Priority to AU2002245317A priority patent/AU2002245317A1/en
Publication of WO2002059377A2 publication Critical patent/WO2002059377A2/fr
Publication of WO2002059377A3 publication Critical patent/WO2002059377A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des gènes dont l'expression est régulée positivement ou négativement dans le cancer du sein. Elle concerne également des procédés et des compositions que l'on peut utiliser dans le diagnostic et le traitement du cancer du sein, ainsi que des procédés qui permettent d'identifier des modulateurs du cancer du sein.
PCT/US2002/002242 2001-01-24 2002-01-24 Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein WO2002059377A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002440703A CA2440703A1 (fr) 2001-01-24 2002-01-24 Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
MXPA03006617A MXPA03006617A (es) 2001-01-24 2002-01-24 Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
EP02713469A EP1425302A2 (fr) 2001-01-24 2002-01-24 Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
JP2002559859A JP2005503760A (ja) 2001-01-24 2002-01-24 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
AU2002245317A AU2002245317A1 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US26396501P 2001-01-24 2001-01-24
US60/263,965 2001-01-24
US26592801P 2001-02-02 2001-02-02
US60/265,928 2001-02-02
US28269801P 2001-04-09 2001-04-09
US60/282,698 2001-04-09
US09/829,472 US20040146862A1 (en) 2000-03-15 2001-04-09 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US09/829,472 2001-04-09
US28859001P 2001-05-04 2001-05-04
US60/288,590 2001-05-04
US29444301P 2001-05-29 2001-05-29
US60/294,443 2001-05-29

Publications (2)

Publication Number Publication Date
WO2002059377A2 WO2002059377A2 (fr) 2002-08-01
WO2002059377A3 true WO2002059377A3 (fr) 2004-04-01

Family

ID=27559443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002242 WO2002059377A2 (fr) 2001-01-24 2002-01-24 Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein

Country Status (6)

Country Link
EP (1) EP1425302A2 (fr)
JP (1) JP2005503760A (fr)
AU (1) AU2002245317A1 (fr)
CA (1) CA2440703A1 (fr)
MX (1) MXPA03006617A (fr)
WO (1) WO2002059377A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP1248800A2 (fr) 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
CA2395832A1 (fr) * 2000-01-25 2001-08-02 Genentech, Inc. Compositions et methodes de traitement de cancer
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
ES2281437T3 (es) 2000-08-22 2007-10-01 Agensys, Inc. Acido nucleico y proteina correspondiente denominada 158p1d7 util para el tratamiento y la deteccion del cancer de vejiga y otros canceres.
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2003000012A2 (fr) * 2001-06-21 2003-01-03 Millennium Pharmaceuticals, Inc. Compositions, necessaires et methodes destines a l'identification, a l'evaluation, a la prevention et au traitement des cancers du sein et de l'ovaire
AU2008201995A1 (en) * 2001-09-18 2008-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treament of tumor
KR101008758B1 (ko) * 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AU2002329061A1 (en) 2001-09-25 2003-04-07 Japan As Represented By The President Of The University Of Tokyo Gene and protein relating to hepatocellular carcinoma
ATE364690T1 (de) 2001-11-09 2007-07-15 Proteologics Inc Posh nukleinsäure, polypeptide und darauf bezogene verfahren
AU2002365104A1 (en) * 2001-12-21 2003-07-15 Biovision Ag Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
JP2005531296A (ja) * 2002-03-04 2005-10-20 アバロン　ファーマシューティカルズ 化学療法のための標的としての癌関連遺伝子
ES2616800T3 (es) 2002-03-13 2017-06-14 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
AU2003244191A1 (en) * 2002-06-26 2004-01-19 Takeda Pharmaceutical Company Preventives/remedies for cancer
WO2004005463A2 (fr) * 2002-07-03 2004-01-15 Aventis Pasteur Inc. Antigenes tumoraux bfa4 et bcy1 servant a prevenir et/ou a traiter le cancer
WO2004016733A2 (fr) * 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
WO2004024884A2 (fr) * 2002-09-16 2004-03-25 Exelixis, Inc. Syt utilises en tant que modificateurs de la voie p21 et procedes d'utilisation
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
CA2506066A1 (fr) 2002-11-15 2004-06-03 Genomic Health, Inc. Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif
GB0227908D0 (en) * 2002-11-29 2003-01-08 Univ London Cancer related methods and means
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP2007524361A (ja) * 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
JP4568716B2 (ja) 2003-02-20 2010-10-27 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を測定するためのイントロンｒｎａの使用
EP1599607A2 (fr) * 2003-03-04 2005-11-30 Arcturus Bioscience, Inc. Signatures de statut er d'un cancer du sein
JP2007525167A (ja) 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
AU2004227018A1 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
WO2004099779A1 (fr) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Produits de diagnostic et de traitement de maladies associees a la serine protease transmembranaire humaine 3 (tmprss3)
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
DE602004024300D1 (de) 2003-05-28 2010-01-07 Takeda Pharmaceutical Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs
CN102605062A (zh) * 2003-05-29 2012-07-25 千年药品公司 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法
CA2524708C (fr) 2003-06-06 2009-10-06 F. Hoffmann-La Roche Ag Utilisation de la proteine cellulaire liant l'acide retinoique (crabp ii), comme marqueur du cancer du sein
EP1651775A2 (fr) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Survie apres cancer du sein et recurrence de ce type de cancer
JP4680898B2 (ja) 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
CA2531967C (fr) 2003-07-10 2013-07-16 Genomic Health, Inc. Algorithme de profile d'expression et test du pronostic du cancer
WO2005005471A2 (fr) 2003-07-11 2005-01-20 Develogen Aktiengesellschaft Utilisation de produits des proteines dg153 ou dg177 secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite et/ou du syndrome metabolique
WO2005015231A1 (fr) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Utilisation de la proteine spermidine synthase (spee) comme marqueur du cancer colorectal
WO2005040804A1 (fr) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Utilisation d'une proteine spee (spermidine synthase) en tant que marqueur du cancer du sein
WO2005040811A1 (fr) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Utilisation de la proteine tip47 comme marqueur du cancer du sein
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
DE602004031368D1 (de) 2003-12-23 2011-03-24 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
AU2005207318B2 (en) * 2004-01-09 2012-02-02 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancers of epithelial origin
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP5813908B2 (ja) 2004-04-09 2015-11-17 ジェノミック ヘルス， インコーポレイテッド 化学療法剤に対する応答を予測するための遺伝子発現マーカー
US7332281B2 (en) 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1747236A1 (fr) * 2004-05-12 2007-01-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (n4) utilise en tant que marqueur prognostique de cancer
WO2005114213A2 (fr) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostic et traitement de maladies associees au recepteur couple aux proteines g npy1 (npy1)
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
EP1621637A1 (fr) * 2004-07-30 2006-02-01 Institut Curie mRNA ou peptide ppGalNac-T6 comme marqueur pour la détection des cellules cancéreuses
CN102443627B (zh) * 2004-08-10 2014-10-29 加的夫生物学有限公司 用于乳腺癌的预后的试剂盒
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
US7622251B2 (en) 2004-11-05 2009-11-24 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (ja) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
WO2006069449A1 (fr) * 2004-12-29 2006-07-06 The University Of British Columbia Activite immunomodulatoire et antiproliferative independante du recepteur de la chimiokine
EP1866436A1 (fr) * 2005-02-28 2007-12-19 Oncotherapy Science, Inc. Gene znfn3a1 associe au cancer du sein
WO2006121208A1 (fr) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphismes de l’element de liaison de e2f-1 et procedes de determination de la sensibilite au cancer
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
CN101278060B (zh) * 2005-07-29 2011-09-07 肿瘤疗法科学股份有限公司 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
RS52804B (en) 2005-12-08 2013-10-31 Medarex Inc. HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE
EP1806587A1 (fr) * 2006-01-07 2007-07-11 Université de Liège Procédé in vitro de criblage de marqueurs biologiques accessibles dans des tissus pathologiques
WO2007120753A2 (fr) * 2006-04-11 2007-10-25 Corixa Corporation Méthodes, compositions et kits de détection et de surveillance d'un cancer de la vessie
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
EP2171082B1 (fr) 2007-06-14 2012-11-28 Oncotherapy Science, Inc. Procedes d'identification d'agents qui modulent la methylation de vegfr1 par smyd3
SI2280721T1 (en) 2008-04-17 2018-02-28 Io Biotech Aps C/O Cobis IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS
EP2303332B1 (fr) 2008-07-15 2014-12-31 Genentech, Inc. Conjugués de dérivés d anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
EP2214019A1 (fr) * 2009-01-28 2010-08-04 Externautics S.p.A. Marqueurs de tumeurs et leurs utilisations
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
WO2011062997A2 (fr) 2009-11-17 2011-05-26 Musc Foundation For Research Development Anticorps monoclonaux humains pour nucléoline humaine
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2011140662A1 (fr) * 2010-05-13 2011-11-17 The Royal Institution For The Advancement Of Learning / Mcgill University Signature cux1 pour déterminer l'évolution clinique d'un cancer
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
PL2621526T3 (pl) 2010-09-29 2018-11-30 Agensys, Inc. Koniugaty leków i przeciwciał (adc), które wiążą białka 191p4d12
CA2816426A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugues d'anticorps alaninyl-maytansinol
US20120269419A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with moments
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
TR201900694T4 (tr) 2012-08-23 2019-02-21 Agensys Inc 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
EP2906297B1 (fr) 2012-10-12 2017-12-06 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
EP2839860B1 (fr) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazépines et ses conjugués
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
CA2887895C (fr) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Conjugues d'anticorps cd19-anti-pyrrolobenzodiazepine
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
CN105102003B (zh) 2012-10-12 2019-03-05 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗psma抗体结合物
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
BR112015021965B1 (pt) 2013-03-13 2022-05-03 Medimmune Limited Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
CA2933557A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes peptidomimetiques et conjugues anticorps-medicament de ceux-ci
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (fr) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Anticorps et conjugués modifiés génétiquement avec de la cystéine
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
PE20170905A1 (es) 2014-09-17 2017-07-12 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas
CA2968447A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugues anticorps-pyrrolobenzodiazepine
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP6671555B2 (ja) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
CA3057748A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polytherapie avec un conjugue anticorps anti-axl-medicament
WO2018229222A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Régimes posologiques pour l'administration d'un cam anti-cd19
WO2019034764A1 (fr) 2017-08-18 2019-02-21 Medimmune Limited Conjugués de pyrrolobenzodiazépine
JP2020534300A (ja) 2017-09-20 2020-11-26 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． タイランスタチン類似体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019189990A1 (fr) * 2018-03-27 2019-10-03 신일제약주식회사 Composition de diagnostic du cancer du sein utilisant de multiples auto-anticorps et kit de diagnostic du cancer du sein l'utilisant
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024031181A1 (fr) * 2022-08-08 2024-02-15 Université de Montréal Nouveaux antigènes pour le cancer et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045328A2 (fr) * 1997-04-09 1998-10-15 Corixa Corporation Compositions therapeutiques et diagnostiques du carcinome mammaire et methodes afferentes
WO1999033869A2 (fr) * 1997-12-24 1999-07-08 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
WO2000022130A2 (fr) * 1998-10-15 2000-04-20 Chiron Corporation Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045328A2 (fr) * 1997-04-09 1998-10-15 Corixa Corporation Compositions therapeutiques et diagnostiques du carcinome mammaire et methodes afferentes
WO1999033869A2 (fr) * 1997-12-24 1999-07-08 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
WO2000022130A2 (fr) * 1998-10-15 2000-04-20 Chiron Corporation Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERTUCCI F ET AL: "Gene expression profiling of primary breast carcinomas using arrays of cancidate genes", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 20, 2000, pages 2981 - 2991, XP002225994, ISSN: 0964-6906 *
BURGER A M ET AL: "Detection of novel genes that are up-regulated (Di12) or down-regulated (T1A12) with disease progression in breast cancer", MEDLINE, XP002217698 *
DATABASE SWISSPROT [online] 1 May 1992 (1992-05-01), "ODPA human", XP002254869, accession no. EBI Database accession no. P08559 *
MARTIN K J ET AL: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
WATSON M A ET AL: "ISOLATION OF DIFFERENTIALLY EXPRESSED SEQUENCE TAGS FROM HUMAN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 17, 1 September 1994 (1994-09-01), pages 4598 - 4602, XP000576043, ISSN: 0008-5472 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
JP2005503760A (ja) 2005-02-10
WO2002059377A2 (fr) 2002-08-01
MXPA03006617A (es) 2004-12-02
CA2440703A1 (fr) 2002-08-01
EP1425302A2 (fr) 2004-06-09
AU2002245317A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
WO2002059377A3 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
WO2002102235A3 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
WO2003025138A3 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
WO2003042661A3 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
WO2003003906A3 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
WO2002030268A3 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
WO2004048938A3 (fr) Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
WO2004063355A3 (fr) Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2002098358A3 (fr) Procedes de diagnostic et de traitement du cancer prostatique androgene-dependant, cancer prostatique subissant un retrait d'androgenes et cancer prostatique androgene-independant
WO2004073657A3 (fr) Methode de diagnostic du cancer, composition et methodes de criblage destinees a identifier des modulateurs du cancer
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
EP2014669A3 (fr) Procédés et compositions de lutte contre le cancer
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
WO2004008147A3 (fr) Diagnostic et prevention de l'invasion des cellules cancereuses
WO2003004989A3 (fr) Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1900827A3 (fr) Procédés et compositions pour la prédiction, le diagnostic, le pronostic et la prévention et le traitement de néoplasies malignes
WO2005047534A3 (fr) Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2004106495A3 (fr) Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003045230A3 (fr) Compositions et procedes contre le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006617

Country of ref document: MX

Ref document number: 2002559859

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002713469

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2440703

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002713469

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002713469

Country of ref document: EP